



# **BAVE NCIO** ® (avelumab)

## **PATIENT ALERT CARD**

**IMPORTANT** - This card contains important safety information of your avelumab treatment. Keep this card with you during your treatment and for another 3 months after your last treatment t with avelumab. Always show it to any healthcare professional involved íπ your treatment.

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side affects you may get. Local ADR Reporting Details: www. medicinesauthority.gov.mt/ adrportal or report to Vivian Corporation Ltd. on 22588600 or pv@viviancorp.com.

Date of preparation May 2023

Malta Medicines Authority on

marketing authorisat**infilan**d has been approved by the This educational material is part of the conditions

## Avelumab

Important safety information to minimize the risk of immune-related side effects

Contact a specialist right away if you develop any of the signs or symptoms described in this card.

For further information, consult the Patient Information Leaflet or call Vivian Corporation Ltd. on 22588600.

Please keep this card with you during your treatment and for 3 months following the end of your treatment with avelumab.

Contact your specialist right away if you develop any signs or symptoms, which may include those listed below:

- · Breathing difficulties
- Cough

- · Yellowing of skin and whites of your eyes (Jaundice)
- · Severe nausea or vomiting
- · Pain on the right side of your stomach area (abdomen)
- Drowsiness
- · Dark urine (teacoloured)
- · Bleeding or bruising more easily than normal
- Feelingless hungry than usual
- Tiredness
- Abnormal liver function tests

### Rowel and stomach

- · Diarrhoea (loose stools)
- · More bowel movements than usual
- · Blood in your stools or dark, tarry, sticky stools
- · Severe stomach (abdomen) pain or tenderness

### Hormone glands

- · Extreme tiredness
- · Rapid heartbeat
- · Increased sweating
- · Changes in mood or behavior, such as irritability or
- foraetfulness
- Feeling cold

- nausea)
- Weight change
- Headache

Endocrine pancreas gland (type 1 diabetes including a serious, sometimes life-threatening problem due to increased acid in the blood produced from diabetes (diabetic ketoacidosis))

- · Feelingmore hungry or thirsty than usual
- · Needing to urinate moreoften
- Weight loss
- Feeling tired
- Having difficulty thinking clearly
  Breath that smells sweet or fruity
- Feeling sick or being sick
- Stomach pain
  Deep or fast breathing

### Kidneys

- Abnormal kidney function tests
- · Urinating less than usual Blood in your urine
- Swelling in your ankles

- Trouble breathing
- Dizziness or fainting
- Fever
- Chest pain and chesttightness

### Pancreas

- · Abdominal pain
- Nausea

· Muscle pain or weakness

### Eve

- Eyepain
- Eye redness
  Sensitivity to light
- · Blurred or cloudy vision Small shapes moving across your f1eld of vision (floaters)
- . Loss of peripheral vision (the ability to see objects at the side of your field of vision)

### Nervous system

### Guilla in-Barre Syndrome

- Numbness
- Muscle weakness
- · Difficulty walking

### Myasthenia gravis, myasthenic syndrome-

Muscle weakness

### Infusion-related reactions

- · Shortness of breath or wheezing
- · Chills or shaking
- Rumny rash or skin wheals
- Flushing Low blood pressure (dizziness, fatique, nausea)
- Fever
- Back pain
- Abdominal pain

## **IMPORTANT**

- · Do not attempt to diagnose or treat side effects vourself
- · Carry this Alert Card with you at all times. especially when you travel, whenever you go to the Accident and Emergency department, or when you must see another doctor, nurse or pharmacist
- · Be sure to notify any healthcare professional you see that you are being treated with avelumab and show them this card

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side-effects directly via: Local ADR Reporting Details: www.medicinesauthority.gov.mt/adrporta I or report to Vivian Corporation Ltd on 22588600 or pv@viviancorp.com Ltd. By reporting side effects you can provide more information on the safety of this medicine.

### IMPORTANT INFORMATION FOR HEALTH CARE PROVIDERS

This patient is being treated with avelumab, which can cause infusion-related reactions as well as immunerelated adverse reactions that involve the lungs, liver, intestines, hormone producing glands (the thyroid, adrenal, pituitary and endocrine pancreas glands), kidneys and other organs. Early diagnosis and appropriate management are essential to minimise any consequences of immune-related adverse reactions.

For suspected immune related adverse reactions. adequate evaluation should be performed to confirm aetiology or exclude other causes.

Please refer to the summary of product characteristics available at

www .ema.europa.eu/en/medicines/human/ EPAR/bavencio

Specific guidelines for managing immunerelated adverse reactions are available in the Summary of Product Characteristics for avelumah

Assess patients for signs and symptoms of pneumonitis, hepatitis, colitis, endocrinopathies including thyroid disorders (hypothyroidism/hyperthyroidism), adrenal insufficiency, type 1 diabetes mellitus, nephritis and renal dysfunction, and other immunerelated adverse reactions reported in patients receiving avelumab: myocarditis including fatal cases, pancreatitis including fatal cases, myositis, hypopituitarism, uveitis, Guillain-Barre syndrome and myasthenia gravis, myasthenic syndrome.

Please consult the Summary of Product Characteristics for Avelumab

https://www.ema.europa.eu/en/medici nes/human/EPAR/bavencio or call Vivian Corporation Ltd on 22588600 for more information.

## IMPORTANT CONTACT

### **INFORMATION** Name of Specialist

(	
Phone	

After-hours Phone

Mv Name

My Phone

Emergency Contact (Name)

**Emergency Contact (Phone)**